Skip to main content

Johnson & Johnson beats on earnings and hikes outlook as medtech, pharmaceutical sales surge

It marks J&J's first quarterly results since the company completed the separation from its consumer health spinoff Kenvue in August.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.